Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years by Goss, et al.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P.E. Goss, J.N. Ingle, K.I. Pritchard, N.J. Robert, H. Muss, J. Gralow, K. Gelmon, T. Whelan, 
K. Strasser-Weippl, S. Rubin, K. Sturtz, A.C. Wolff, E. Winer, C. Hudis, A. Stopeck, J.T. 
Beck, J.S. Kaur, K. Whelan, D. Tu, and W.R. Parulekar
Abstract
BACKGROUND—Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or 
after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast 
cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years 
may further reduce the risk of breast-cancer recurrence.
METHODS—We conducted a double-blind, placebo-controlled trial to assess the effect of the 
extended use of letrozole for an additional 5 years. Our primary end point was disease-free 
survival.
RESULTS—We enrolled 1918 women. After a median follow-up of 6.3 years, there were 165 
events involving disease recurrence or the occurrence of contralateral breast cancer (67 with 
letrozole and 98 with placebo) and 200 deaths (100 in each group). The 5-year disease-free 
survival rate was 95% (95% confidence interval [CI], 93 to 96) with letrozole and 91% (95% CI; 
89 to 93) with placebo (hazard ratio for disease recurrence or the occurrence of contralateral breast 
cancer, 0.66; P = 0.01 by a two-sided log-rank test stratified according to nodal status, prior 
adjuvant chemotherapy, the interval from the last dose of aromatase-inhibitor therapy, and the 
duration of treatment with tamoxifen). The rate of 5-year overall survival was 93% (95% CI, 92 to 
95) with letrozole and 94% (95% CI, 92 to 95) with placebo (hazard ratio, 0.97; P = 0.83). The 
annual incidence rate of contralateral breast cancer in the letrozole group was 0.21% (95% CI, 
0.10 to 0.32), and the rate in the placebo group was 0.49% (95% CI, 0.32 to 0.67) (hazard ratio, 
0.42; P = 0.007). Bone-related toxic effects occurred more frequently among patients receiving 
letrozole than among those receiving placebo, including a higher incidence of bone pain, bone 
fractures, and new-onset osteoporosis. No significant differences between letrozole and placebo 
were observed in scores on most subscales measuring quality of life.
CONCLUSIONS—The extension of treatment with an adjuvant aromatase inhibitor to 10 years 
resulted in significantly higher rates of disease-free survival and a lower incidence of contra-lateral 
breast cancer than those with placebo, but the rate of overall survival was not higher with the 
aromatase inhibitor than with placebo. (Funded by the Canadian Cancer Society and others; 
ClinicalTrials.gov numbers, NCT00003140 and NCT00754845.)
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The risk of recurrence of hormone-receptor–positive early breast cancer continues 
indefinitely.1 Long-term reduction in the risk of recurrence has been achieved with the 
antiestrogen agent tamoxifen, aromatase inhibitors, or a combination of the two. These 
treatments are administered in a variety of adjuvant regimens, including tamoxifen for 10 
years, tamoxifen for up to 5 years followed by an aromatase inhibitor for 5 years, or an 
initial aromatase inhibitor for 5 years.2–4 Extrapolating from these results, many patients 
have chosen to continue taking an aromatase inhibitor for more than 5 years (if they do not 
have unacceptable side effects), despite the lack of specific data on its value and pending the 
results of clinical trials. The MA.17R trial was a North American Breast Cancer Group trial 
that was coordinated by the Canadian Cancer Trials Group. The trial examined the effects of 
treatment with an aromatase inhibitor for 10 years rather than just 5 years after any duration 
of prior treatment with tamoxifen.
METHODS
STUDY DESIGN AND PARTICIPANTS
The MA.17R trial was a phase 3, randomized, double-blind, placebo-controlled trial 
involving postmenopausal women with primary breast cancer who had received 4.5 to 6 
years of adjuvant therapy with an aromatase inhibitor, preceded in most patients by 
treatment with tamoxifen. Within 2 years after completing treatment with the aromatase 
inhibitor, patients were randomly assigned5 to receive 2.5 mg of letrozole or placebo orally 
once a day for another 5 years. Participants were stratified according to lymph-node status, 
prior receipt of adjuvant chemotherapy, the interval between the last dose of aromatase 
inhibitor and randomization, and the duration of prior receipt of tamoxifen. Women were 
eligible to participate in the trial if they were disease-free after having completed 4.5 to 6 
years of therapy with any aromatase inhibitor. Further eligibility criteria at enrollment 
included hormone-receptor positivity in the primary tumor (unknown hormone-receptor 
status was permitted only for patients who had participated in the MA.17 trial), performance 
status of less than 3 on the Eastern Cooperative Oncology Group scale (a 5-point scale on 
which higher scores indicate more disease-related disability), and a minimum life 
expectancy of at least 5 years. Exclusion on the basis of age alone was not permitted.
OVERSIGHT
The institutional review board at each participating institution approved the protocol, which 
is available with the full text of this article at NEJM.org. All patients provided written 
informed consent. The trial drug, letrozole, and funding support were provided by Novartis. 
The Canadian Cancer Trials Group was responsible for the design of the study, the 
development of the protocol, and the collection and maintenance of the data. All the authors, 
with assistance from the staff at the central office of the Canadian Cancer Trials Group, 
contributed to the writing of the manuscript and to the decision to submit the manuscript for 
publication and vouch for the accuracy and completeness of the data reported and adherence 
to the protocol. Novartis reviewed the protocol and all amendments before these documents 
were submitted regulatory agencies and research ethics boards. Novartis did not contribute 
to the accrual, analysis, or interpretation of the data or to the writing of the manuscript. No 
one who is not an author contributed to the manuscript.
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ASSESSMENTS
Clinical evaluations, which were performed annually, included assessments of new bone 
fracture and new-onset osteoporosis, routine blood work, mammography, and assessment of 
toxic effects. Subsequent new diagnoses were reported at follow-up visits. Bone mineral 
density was measured by means of dual-energy x-ray absorptiometry, and scans were 
obtained within 12 months after study entry, every 2 years thereafter, and at the completion 
of treatment. Treatment was discontinued if there was a serious intercurrent illness, 
unacceptable toxic effects, or disease recurrence or if requested by the patient. Adherence to 
study procedures was confirmed during all follow-up visits if a participant answered “yes” 
when asked if she had “been taking the study medication by mouth once per day.” Adverse 
events were assessed with the use of the National Cancer Institute Common Toxicity 
Criteria, version 2.0, and quality of life with the use of the Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) and the Menopause-Specific Quality of Life (MENQOL) 
questionnaire at baseline and at 12, 24, 36, 48 and 60 months.6,7 Interim safety analyses 
were reviewed twice yearly by the independent data and safety monitoring committee of the 
Canadian Cancer Trials Group. The quality-of-life analysis involved between-group 
comparisons of the change in scores from baseline on the SF-36 physical and mental 
component summary scores and its eight subscales (physical functioning, role–physical, 
bodily pain, general health, vitality, social functioning, role–emotional, and mental health) 
and on the four MENQOL symptom subscales (vasomotor, psychosocial, physical, and 
sexual). SF-36 scores range from 0 to 100, with higher scores indicating better quality of 
life, and MENQOL scores range from 1 to 8, with higher scores indicating more bothersome 
symptoms. The minimum clinically important difference for SF-36 and MENQOL scores is 
5 and 0.5, respectively.8,9 (See Section S1 in the Supplementary Appendix, available at 
NEJM.org, for the methods used to perform the analyses.) Women with at least one 
assessment were included in the quality-of-life analyses.
TRIAL END POINTS
The primary end point was disease-free survival, which was defined as the time from 
randomization to recurrence of breast cancer (in the breast or chest wall or at nodal or 
metastatic sites) or the development of a new primary breast cancer. The occurrence of a 
second type of cancer or death without breast cancer recurrence were not included as events 
in the analysis of disease-free survival; data for patients who died without breast cancer 
recurrence were censored at the date of death. Secondary end points included overall 
survival, the incidence of contralateral breast cancer, quality of life, and long-term safety.
STATISTICAL ANALYSIS
On the basis of the 43% lower hazard of recurrence found with letrozole as compared with 
placebo in the preceding MA.17 trial,10 we hypothesized that a 33% lower hazard of 
recurrence with letrozole as compared with placebo would be seen in the MA.17R trial. We 
calculated that for the study to have 80% power, at a two-sided 0.05 level, to detect this 
improvement, 196 events would need to be observed, and we estimated that the target 
enrollment for that number of events would be 1800 patients. On the basis of the estimate of 
disease-free survival of 89% at 5 years in the placebo group, it was projected that 196 events 
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would be observed after patients were followed for 4 years. At the 6-year point, by June 4, 
2015, only 176 events had been observed and, on the basis of the relatively small loss in the 
power of the study, a continued decline in the event rate, and limitations in resources, the 
trial design was amended, with the primary analysis becoming time-based rather than event-
based. These changes were approved by the data and safety monitoring committee, the 
institutional review boards of the participating institutions, and other regulatory bodies. The 
final database, which was locked on November 13, 2015, had 165 events (cleaned data), 
providing 80% power to detect a hazard ratio of 0.655 for disease-free survival.
Analyses of pretreatment characteristics and efficacy end points were based on data from all 
patients who underwent randomization. Analyses of safety and the effects of exposure to the 
study medication included all participants who received at least one dose of the trial 
medication. A log-rank test with adjustment for stratification factors performed at the time 
of randomization was the primary method that we used for the analysis of time-to-event 
outcomes; binary outcomes were assessed with the use of Fisher’s exact test, and continuous 
outcomes with the use of the Wilcoxon test. All comparisons between the two groups were 
made with the use of a two-sided test at an alpha level of 5%, unless otherwise specified. No 
adjustments were made for multiplicity of inferences for multiple clinical end points.
We report results for the primary outcomes and selected secondary outcomes. Other 
secondary outcomes are listed in the protocol.
RESULTS
STUDY POPULATION AND DURATION OF TREATMENT
The target enrollment was reached on May 8, 2009, which was 4.5 years after randomization 
began. A total of 1918 patients were randomly assigned to receive letrozole (959 patients) or 
placebo (959 patients) (see Fig. S1 in the Supplementary Appendix). Randomization with 
stratification was used to ensure that the treatment groups were well balanced at baseline 
(Table 1). The rate of adherence to the study regimen was 62.5% among the patients 
receiving letrozole and 62.3% among those receiving placebo.
The median time between the initial diagnosis of breast cancer and randomization was 10.6 
years (interquartile range, 7.6 to 11.5). The median duration of prior treatment with 
tamoxifen was 5 years, with 68.5% of patients having received tamoxifen for 4.5 to 5.5 years 
and 20.7% having received no tamoxifen. The median duration of prior treatment with an 
aromatase inhibitor was 5 years, with 95.4% having received 4.5 to 5.5 years of treatment. 
Almost all patients (99.5%) had been without continuous breaks of longer than 6 months 
while taking their prior aromatase inhibitor. The median interval between the last dose of 
aromatase inhibitor and randomization was less than 6 months for 90% of participants, and 
the median duration of the study regimen was 5 years (mean, 4.3 years). Median follow-up 
was 75 months (6.3 years).
EFFICACY END POINTS
A total of 165 participants had an event involving disease recurrence or the occurrence of 
contralateral breast cancer (67 in the letrozole group and 98 in the placebo group). Among 
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these patients, 55 in the letrozole group and 68 in the placebo group had recurrent breast 
cancer, and 13 and 31, respectively, had contralateral breast cancer (Table 2). The Kaplan–
Meier curves for disease-free survival are shown in Figure 1A. The rate of 5-year disease-
free survival was 95% (95% confidence interval [CI], 93 to 96) in the letrozole group and 
91% (95% CI, 89 to 93) in the placebo group. The hazard ratio involving disease recurrence 
or the occurrence of contralateral breast cancer with letrozole versus placebo was 0.66 (95% 
CI, 0.48 to 0.91; P = 0.01).
A prespecified sensitivity analysis of disease-free survival that included all deaths from 
breast cancer as events yielded the same results as the primary analysis because all patients 
who died of breast cancer also had recurrence before or at the time of their death. A post hoc 
sensitivity analysis of disease-free survival that included all deaths as events showed a rate 
of 5-year disease-free survival of 90% (95% CI, 88 to 92) with letrozole versus 88% (95% 
CI, 86 to 90) with placebo. The hazard ratio for disease recurrence, the occurrence of 
contralateral breast cancer, or death with letrozole as compared with placebo was 0.80 (95% 
CI, 0.63 to 1.01; P = 0.06); in a multivariate analysis that was adjusted for stratification 
factors and the duration of aromatase-inhibitor therapy received before the trial, the hazard 
ratio was 0.79 (95% CI, 0.63 to 1.00; P=0.05).
The effect of letrozole on disease-free survival was also explored in subgroups defined 
according to each stratification factor and according to the duration of prior treatment with 
an aromatase inhibitor; all the subgroups were prespecified in the analysis plan. The superior 
effect of letrozole was observed in all subgroups, and no significant interactions were 
observed, indicating a homogeneity of treatment effect across all subgroups (Fig. S2 in the 
Supplementary Appendix).
A total of 200 participants had died by the time of data cutoff (100 in each study group). The 
major causes of death in the letrozole and placebo groups were breast cancer (31 and 34 
deaths, respectively), other primary cancers (26 and 25), and cardiovascular events (14 and 
11). The Kaplan–Meier curves for overall survival are shown in Figure 1B. The rate of 5-
year overall survival was 93% (95% CI, 92 to 95) in the letrozole group and 94% (95% CI, 
92 to 95) in the placebo group, with a hazard ratio for death of 0.97 (95% CI, 0.73 to 1.28; P 
= 0.83). No significant difference in overall survival between letrozole and placebo was 
found in any of the prespecified subgroups.
The annual incidence rate of contralateral breast cancer was 0.21% (95% CI, 0.10 to 0.32) in 
the letrozole group and 0.49% (95% CI, 0.32 to 0.67) in the placebo group (P = 0.007), with 
a hazard ratio of 0.42 (95% CI, 0.22 to 0.81). The cumulative incidence plot for the time to 
the development of contralateral breast cancer is shown in Figure 2.
SAFETY
The incidence of most toxic effects was similar in the two groups, with the exception of 
bone-related toxic effects, which were more common in the letrozole group (Table 3). Few 
women discontinued treatment because of toxic effects (5.4% in the letrozole group vs. 3.7% 
in the placebo group).
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Whereas patients receiving letrozole had a mean loss of bone mineral density in the total hip 
(mean loss, −3.2%) and an increase of 1.4% in the lumbar spine at the time that treatment 
was discontinued, there was an increase in bone mineral density in both the hip and the spine 
in patients receiving placebo (mean gain in the hip, 22.4%, and in the spine, 4.5%). The 
between-group difference in the mean change in bone mineral density was significant, 
favoring placebo (P<0.001). A significantly greater number of participants receiving 
letrozole than those receiving placebo had a T score at the lumbar spine that was less than 
−2.5 at any time after baseline (10% vs. 7%, P = 0.03). A similar percentage of patients in 
the two groups used bone-protecting medications during the trial, including calcium 
supplements (86.1% in both groups), vitamin D supplements (84.5% in both groups), a 
selective estrogen-receptor modulator (0.3% in both groups), and bisphosphonates (46.2% in 
the letrozole group and 46.6% in the placebo group). Among 133 patients receiving letrozole 
who had a fracture during the trial period, 56% were taking bisphosphonates, 90% were 
taking a calcium supplement, and 86% were taking a vitamin D supplement; among 88 
patients receiving placebo who had a fracture during protocol therapy, 55% were taking 
bisphosphonates, 86% a calcium supplement, and 88% a vitamin D supplement.
QUALITY OF LIFE
In both groups, more than 85% of the participants completed the quality-of-life assessment 
at each time point. No significant between-group differences were observed in the SF-36 
summary scores or in the majority of the subscale scores. Overall, the reduction in scores 
(indicating worse quality of life) was greater among women in the letrozole group than 
among those in the placebo group in the role–physical subscale (between-group difference in 
the change in score, 3.2; P = 0.009). The interaction between group assignment and time was 
significant for the bodily pain (P = 0.03) and the role–emotional (P = 0.03) subscales, 
indicating a change in between-group differences over time. Specifically, bodily pain was 
greater with letrozole than with placebo at 12, 24, and 36 months but lower at months 48 and 
60. However, when single time points were compared, the between-group difference was of 
only borderline significance at 12 months (P = 0.07). Regarding the role–emotional sub-
scale, women receiving letrozole had better scores than those receiving placebo at months 
12, 36, and 60, but their scores were worse than the scores for those receiving placebo at 
months 24 and 48. Comparison at single time points showed a significant difference only at 
60 months, in favor of letrozole (change in score, −3.1 with letrozole vs. −8.6 with placebo; 
P = 0.01). No significant between-group differences were observed on any of the four 
MENQOL symptom subscales.
DISCUSSION
The MA.17R trial explored the effect of extending adjuvant treatment with an aromatase 
inhibitor beyond 5 years in women with early breast cancer. We showed that treatment with 
an aromatase inhibitor for an additional 5 years after initial treatment for 4.5 to 6 years was 
beneficial in preventing disease recurrence, independent of nodal status, prior adjuvant 
chemotherapy, time since the last dose of aromatase inhibitor, and duration of prior therapy 
with tamoxifen or an aromatase inhibitor. The risk of disease recurrence and contralateral 
breast cancer was significantly lower (by 34%) among women who continued aromatase 
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inhibitor for 10 years than among women who received placebo after the initial 5 years of 
aromatase-inhibitor therapy. No overall difference in survival was noted at a median follow-
up of 6.3 years. The significant benefit in disease-free survival includes not only a 
numerically larger reduction in events of local, regional, and distant recurrence but also an 
apparently greater proportional reduction in events of contralateral breast cancer, which may 
partly explain the absence thus far of an observed overall survival benefit.
For patients receiving up-front treatment with tamoxifen, the extension of tamoxifen2,3 or an 
aromatase inhibitor to 10 years has been shown to be beneficial in reducing the ongoing risk 
of recurrence.10,11 However, most postmenopausal patients with hormone-receptor–positive 
early breast cancer now receive 5 years of treatment with an aromatase inhibitor as up-front 
therapy. For this overwhelming majority of patients with breast cancer, it was previously 
unclear whether the extension of treatment with an aromatase inhibitor beyond 5 years 
would be beneficial.
As patients in the placebo group stopped taking the aromatase inhibitor and quickly reverted 
to normal postmenopausal estrogen levels, they had an improvement in bone health, as 
would be expected when aromatase-inhibitor therapy is stopped.12 In addition, a 
significantly greater percentage of the women taking letrozole than those taking placebo had 
both new-onset osteoporosis and more clinical fractures — either major osteoporotic 
fractures (i.e., fragility fractures at the typical osteoporotic sites of the proximal femur [hip], 
thoracic or lumbar vertebrae [spine], distal forearm [wrist], or proximal humerus [shoulder]) 
or other fragility fractures (i.e., fragility fractures at any other skeletal site). The increases in 
bone mineral density that were observed among patients receiving placebo were anticipated. 
Only a minority of the fractures in both groups were located in the hip, spine, pelvis, or 
femur, and no significant change in physical health was recorded in either group, perhaps 
because most of the women in both groups took bone-protecting supplements or medications 
during the study. Overall, the low incidence of reported toxic effects is probably due to self-
selection on the part of study participants who had had few unacceptable side effects through 
the first 5 years of aromatase-inhibitor therapy and were thus willing to undergo another 5 
years of treatment. It is also reassuring that there were no significant between-group 
differences in the outcomes related to most measures of quality of life. The significant 
differences in favor of placebo were observed in only one subscale of the SF-36 — role 
function related to physical health — but the difference (3.2 points) was less than the 
minimum clinically important difference (5 points on a 100-point scale).8
The validity of the adherence data may be limited because we used a measure that relies on 
self-report. The rates of adherence observed were at the lower end of the range reported in 
other studies of early adjuvant endocrine therapy on the basis of longitudinal claims 
data13,14 or combinations of prescription records and physician recall.15
Our study shows that it is safe and beneficial for postmenopausal patients with hormone-
receptor–positive breast cancer to take an aromatase inhibitor as adjuvant therapy for 5 years 
after initial treatment. Although most post-menopausal patients now receive an aromatase 
inhibitor as up-front therapy, only 21% of the patients in the MA.17R trial had not been 
previously treated with tamoxifen. Although the hazard ratios for disease progression and 
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contralateral breast cancer were similar among patients with different durations of prior 
tamoxifen exposure and no interaction effects between study regimen and duration of prior 
tamoxifen exposure were observed in our study, it is likely that the benefits of treatment, 
toxic effects, and quality of life differ among these groups. It is conceivable, for example, 
that since the baseline hazard of recurrence declines over time, the absolute benefit of 
extended endocrine therapy is higher in the first few years after diagnosis and declines over 
time (in the presence of similar hazard ratios, as shown). Consequently, women who are 
discontinuing treatment after having received an aromatase inhibitor for 5 years without 
prior treatment with tamoxifen might be the ones who realize the most benefit. Ultimately, 
the decision of whether a patient should receive prolonged therapy with an aromatase 
inhibitor will depend largely on the extent of its effect on her in terms of toxic effects and 
quality of life, the extent to which bone mineral density is maintained, as indicated by 
sequential scans, and the patient’s individual risk of disease recurrence.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Kaplan–Meier Curves for Disease-free and Overall Survival.
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Figure 2. 
Cumulative Incidence of Contralateral Breast Cancer.
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Table 1
Baseline Characteristics.*
Characteristic Letrozole (N = 959) Placebo (N = 959) Total (N = 1918)
Age — yr†
 Median 65.6 64.8 65.1
 Interquartile range 60.3–72.0 59.6–71.1 60.0–71.5
Time from first diagnosis of breast cancer — yr
 Median 10.6 10.6 10.6
 Interquartile range 7.5–11.5 7.8–11.6 7.6–11.5
Tumor stage at diagnosis — no. (%)‡
 T1–T2 865 (90.2) 870 (90.7) 1735 (90.5)
 T3–T4 87 (9.1) 79 (8.2) 166 (8.7)
 TX 7 (0.7) 10 (1.0) 17 (0.9)
Nodal stage of disease at diagnosis — no. (%)§
 N0 446 (46.5) 448 (46.7) 894 (46.6)
 N1 456 (47.5) 455 (47.4) 911 (47.5)
 N2–N3 36 (3.8) 39 (4.0) 75 (3.9)
 NX 21 (2.2) 17 (1.8) 38 (2.0)
Hormone-receptor status: estrogen, progesterone, or both — no. (%)
 Positive 945 (98.5) 950 (99.1) 1895 (98.8)
 Negative 3 (0.3) 2 (0.2) 5 (0.3)
 Unknown or missing 11 (1.1) 7 (0.7) 18 (0.9)
Treatment with tamoxifen — yr
 Median 5.0 5.0 5.0
 Interquartile range 2.0–5.0 2.0–5.0 2.0–5.0
Duration of tamoxifen therapy — no. (%)
 0 yr 199 (20.8) 198 (20.6) 397 (20.7)
 >0 to <2 yr 40 (4.2) 40 (4.2) 80 (4.2)
 2 to <4.5 yr 43 (4.5) 29 (3.0) 72 (3.8)
 4.5 to 6 yr 670 (69.9) 684 (71.3) 1354 (70.6)
 >6 yr 7 (0.7) 8 (0.8) 15 (0.8)
Duration of previous aromatase-inhibitor therapy¶
 Median (interquartile range) — yr 5.0 (5.0–5.1) 5.0 (5.0–5.1) 5.0 (5.0–5.1)
 Distribution — no. (%)
  <4.5 yr 3 (0.3) 2 (0.2) 5 (0.3)
  4.5–6 yr 949 (99.0) 950 (99.1) 1899 (99.0)
  >6 yr 7 (0.7) 6 (0.6) 13 (0.7)
  Data missing 0 1 (0.1) 1 (0.1)
*
There were no significant differences between the groups in baseline characteristics, except as noted.
N Engl J Med. Author manuscript; available in PMC 2017 January 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Goss et al. Page 14
†
P<0.05 for the comparison between treatment groups at baseline.
‡
T1–T2 indicates that the tumor is ≤50 mm in its greatest dimension, T3–T4 that the tumor is >50 mm in its greatest dimension, and TX that the 
size of the tumor cannot be assessed.
§N0 indicates that there were no regional metastases to lymph nodes, N1 indicates nodal stage metastases, N2–N3 indicates advanced nodal stage 
metastases, and NX indicates that regional lymph nodes could not be assessed.
¶Very few patients continued to take their original aromatase inhibitor after randomization.
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Table 2
Recurrence of Breast Cancer or Occurrence of Contralateral Breast Cancer.
Variable Letrozole (N = 959) Placebo (N = 959)
number (percent)
Patients with a recurrence of the primary cancer or with contralateral breast cancer 67 (7.0) 98 (10.2)
Recurrence*† 55 (5.7) 68 (7.1)
 Local breast 8 (0.8) 10 (1.0)
 Local chest wall 6 (0.6) 7 (0.7)
 Regional 5 (0.5) 13 (1.4)
 Distant 42 (4.4) 53 (5.5)
  Ascites 1 (0.1) 4 (0.4)
  Bone 28 (2.9) 37 (3.9)
  Brain 3 (0.3) 2 (0.2)
  Liver 11 (1.1) 12 (1.3)
  Lung 14 (1.5) 14 (1.5)
  Bone marrow 1 (0.1) 2 (0.2)
  Omentum 1 (0.1) 0
  Peritoneum 1 (0.1) 0
  Pleural effusion 5 (0.5) 4 (0.4)
  Pleura 1 (0.1) 2 (0.2)
  Other 8 (0.8) 12 (1.3)
Contralateral breast cancer† 13 (1.4) 31 (3.2)
*
Patients may have had more than one site of recurrence.
†One patient in each group had both local recurrence and contralateral breast cancer.
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Table 3
Adverse Events.*
Event Letrozole (N = 959) Placebo (N = 954) P Value
number (percent)
Toxic effect during receipt of trial regimen
Edema 158 (16) 136 (14) 0.19
Hypertension 157 (16) 145 (15) 0.48
Hot flashes 360 (38) 354 (37) 0.84
Fatigue 346 (36) 355 (37) 0.61
Constipation 117 (12) 140 (15) 0.10
Diarrhea 105 (11) 81 (8) 0.07
Arthritis 317 (33) 288 (30) 0.18
Hypercholesterolemia 203 (21) 184 (19) 0.31
Dizziness 145 (15) 139 (15) 0.74
Headache 151 (16) 138 (14) 0.43
Insomnia 269 (28) 243 (25) 0.20
Arthralgia 513 (53) 475 (50) 0.10
Myalgia 268 (28) 240 (25) 0.31
Bone pain 174 (18) 133 (14) 0.01
Dyspnea 148 (15) 165 (17) 0.27
Vaginal dryness 102 (11) 96 (10) 0.68
Elevated alkaline phosphatase level — no./total no. (%)† 111/928 (12) 78/916 (9) 0.01
Elevated aspartate aminotransferase level — no./total no. (%)† 133/928 (14) 131/915 (14) 0.92
Elevated alanine aminotransferase level — no./total no. (%)† 97/909 (11) 128/894 (14) 0.02
Bone fracture‡ 133 (14) 88 (9) 0.001
 Spine 17 (2) 9 (1) 0.12
 Wrist 27 (3) 16 (2) 0.09
 Pelvis 1 (<1) 7 (1) 0.08
 Hip 7 (1) 6 (1) 0.79
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Event Letrozole (N = 959) Placebo (N = 954) P Value
number (percent)
 Femur 9 (1) 4 (<1) 0.17
 Tibia 5 (1) 4 (<1) 0.74
 Ankle 19 (2) 11 (1) 0.14
 Other 68 (7) 48 (5) 0.06
New-onset osteoporosis 109 (11) 54 (6) <0.001
Cardiovascular event 116 (12) 98 (10) 0.21
Toxic effect after discontinuation of trial regimen
Hot flashes 25 (3) 17 (2) 0.22
Arthralgia 22 (2) 24 (3) 0.75
Hypertension 8 (1) 4 (<1) 0.25
Superventricular arrhythmia 6 (1) 3 (<1) 0.32
Bone fracture‡ 54 (6) 57 (6) 0.75
 Spine 13 (1) 9 (1) 0.40
 Wrist 4 (<1) 4 (<1) 1
 Pelvis 3 (<1) 4 (<1) 0.70
 Hip 5 (1) 0 0.07
 Femur 2 (<1) 7 (1) 0.09
 Tibia 3 (<1) 2 (<1) 0.65
 Ankle 3 (<1) 6 (1) 0.31
 Other 32 (3) 31 (3.2) 0.92
New-onset osteoporosis 20 (2) 11 (1.2) 0.11
*With the exception of bone toxic effects, for which all adverse events are listed independently of incidence, the data shown refer to adverse events 
of at least grade 1 for which the incidence in the two groups differed by more than 1% or for which the incidence was at least 10% in either group. 
Grades were assigned in accordance with the National Cancer Institute Common Toxicity Criteria, version 2.0.
†
The denominator for these laboratory abnormalities is for the number of women for whom the laboratory evaluation was performed. These 
evaluations were required only during protocol therapy.
‡
Each patient may have had more than one fracture.
N Engl J Med. Author manuscript; available in PMC 2017 January 21.
